Your browser doesn't support javascript.
loading
Long-term direct oral anticoagulation in primary osteonecrosis with elevated plasminogen activation inhibitor.
Haydock, Maria Monica; Elhamdani, Shahed; Alsharedi, Mohamed.
Afiliação
  • Haydock MM; Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, UK.
  • Elhamdani S; Allegheny General Hospital, Pittsburgh, PA, USA.
  • Alsharedi M; Joan C Edwards School of Medicine, Marshall University, Huntington, WV, USA.
SAGE Open Med Case Rep ; 7: 2050313X19827747, 2019.
Article em En | MEDLINE | ID: mdl-30783528
ABSTRACT
Osteonecrosis is a pathological condition that could lead to a debilitating physical disease and impede daily activities. It is generally categorised into aetiology - primary (idiopathic) or secondary. When direct damage to the bone vasculature or direct injury of the bone marrow is related to an identifiable cause such as traumatic injuries, steroid or bisphosphonate use, increased alcohol intake, sickle cell disease, autoimmune diseases, chemotherapy or malignancy, it is categorised as secondary osteonecrosis. On the other hand, osteonecrosis wherein the mechanisms of development are not fully understood is categorised as primary or idiopathic osteonecrosis. This category includes inherited thrombophilia and hypofibrinolysis as potential causes. There are no clear guidelines or general agreements about anticoagulation treatment and duration in primary osteonecrosis due to thrombophilia or hypofibrinolysis. We report a case of primary osteonecrosis associated with hypofibrinolysis and successful control with lifelong direct oral anticoagulation therapy.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article